Cempra quiet period ends March 14

By Renaissance Capital,

Shutterstock photo

Cempra, a biotech developing potent antibiotics to fight pneumonia and skin infections, will see its quiet period end on 3/14/12. On 2/2/12, the company raised $50.4 million by offering 8,400,000 shares at $6.00, below the range of $11.00 to $13.00. Stifel Nicolaus Weisel, Leerink Swann, and Cowen & Company acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing IPOs
Referenced Stocks: CEMP

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com